A Mouse model of acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3601-3613

  Harris, Greg ^a   Lee, Rhonda Kuo ^a   Lam, Christopher K ^b   Kanzaki, Gregory ^b   Patel, Girishchandra B ^a   Xu, H Howard ^b   Chen, Wangxue ^a,c  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c BROCK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; GATIFLOXACIN; GENTAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIPENEM; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; LEVOFLOXACIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MEROPENEM; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PIPERACILLIN; RANTES; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BRONCHOPNEUMONIA; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL; WEIGHT REDUCTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL VACCINES; BODY WEIGHT; BRONCHOPNEUMONIA; DISEASE MODELS, ANIMAL; FEMALE; IMIPENEM; IMMUNIZATION; LUNG; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PNEUMONIA, BACTERIAL; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84880266527     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00944-13     Document Type: Article

References (38)

1. Hartzell JD, Kim AS, Kortepeter MG, Moran KA. 2007. Acinetobacter pneumonia: a review. Med. Gen. Med. 9:4.
2. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, Hsueh PR. 2007. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin. Microbiol. Infect. 13: 196-198.
3. Gaynes R, Edwards JR. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
4. Fournier PE, Richet H. 2006. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. 42:692-699.
5. McConnell MJ, Actis L, Pachon J. 2012. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol. Rev. [Epub ahead of print.] doi:10.1111/j.1574-6976 .2012.00344.x.
6. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. 1997. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob. Agents Chemother. 41:345-351.
7. van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W. 2007. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect. Immun. 75:5597-5608.
8. Renckens R, Roelofs JJ, Knapp S, de Vos AF, Florquin S, van der Poll T. 2006. The acute-phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter baumannii pneumonia. J. Infect. Dis. 193:187-195.
9. Knapp S, Wieland CW, Florquin S, Pantophlet R, Dijkshoorn L, Tshimbalanga N, Akira S, van der Poll T. 2006. Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am. J. Respir. Crit. Care Med. 173:122-129.
10. Qiu H, Kuo Lee R, Harris G, Chen W. 2009. High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils. Microbes Infect. 11:946-955.
11. Russo TA, MacDonald U, Beanan JM, Olson R, MacDonald IJ, Sauberan SL, Luke NR, Schultz LW, Umland TC. 2009. Penicillinbinding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. J. Infect. Dis. 199:513-521.
12. Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, Sayood K, Iwen PC, Skaar EP, Dunman PM. 2010. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect. Immun. 78:1952-1962.
13. Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, Schultz LW, Umland TC, Campagnari AA. 2010. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect. Immun. 78:3993-4000.
14. Luke NR, Sauberan SL, Russo TA, Beanan JM, Olson R, Loehfelm TW, Cox AD, St Michael F, Vinogradov EV, Campagnari AA. 2010. Identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis. Infect. Immun. 78:2017-2023.
15. March C, Regueiro V, Llobet E, Moranta D, Morey P, Garmendia J, Bengoechea JA. 2010. Dissection of host cell signal transduction during Acinetobacter baumannii-triggered inflammatory response. PLoS One 5:e10033. doi:10.1371/journal.pone.0010033.
16. Qiu H, Kuolee R, Harris G, Chen W. 2009. Role of NADPH phagocyte oxidase in host defense against acute respiratory Acinetobacter baumannii infection in mice. Infect. Immun. 77:1015-1021.
17. Eveillard M, Soltner C, Kempf M, Saint-André Lemarié J-PC, Randrianarivelo C, Seifert H, Wolff M, Joly-Guillou M-L. 2010. The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia. J. Infect. 60:154-161.
18. Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin JH, Kim JM, Lee YC, Seol SY, Cho DT, Lee JC. 2009. Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins. FEMS Microbiol. Lett. 301:224-231.
19. King LB, Swiatlo E, Swiatlo A, McDaniel LS. 2009. Serum resistance and biofilm formation in clinical isolates of Acinetobacter baumannii. FEMS Immunol. Med. Microbiol. 55:414-421.
20. de Breij A, Dijkshoorn L, Lagendijk E, van der Meer J, Koster A, Bloemberg G, Wolterbeek R, van den Broek P, Nibbering P. 2010. Do biofilm formation and interactions with human cells explain the clinical success of Acinetobacter baumannii? PLoS One 5:e10732. doi:10.1371/journal.pone.0010732.
21. Bentancor LV, Routray A, Bozkurt-Guzel C, Camacho-Peiro A, Pier GB, Maira-Litran T. 2012. Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections. Infect. Immun. 80:3381-3388.
22. Chang HC, Wei YF, Dijkshoorn L, Vaneechoutte M, Tang CT, Chang TC. 2005. Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J. Clin. Microbiol. 43:1632-1639.
23. Valentine SC, Contreras D, Tan S, Real LJ, Chu S, Xu HH. 2008. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J. Clin. Microbiol. 46:2499-2507.
24. Chen W, Havell EA, Moldawer LL, McIntyre KW, Chizzonite RA, Harmsen AG. 1992. Interleukin 1: an important mediator of host resistance against Pneumocystis carinii. J. Exp. Med. 176:713-718.
25. Chen W, Kuo Lee R, Shen H, Conlan JW. 2004. Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb. Pathog. 36:311-318.
26. Yan H, Kuo Lee R, Tram K, Qiu H, Zhang J, Patel GB, Chen W. 2009. 3=,5=-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. Biochem. Biophys. Res. Commun. 387:581-584.
27. Breslow JM, Meissler JJ, Jr, Hartzell RR, Spence PB, Truant A, Gaughan J, Eisenstein TK. 2011. Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance. Infect. Immun. 79:3317-3327.
28. de Breij A, Haisma EM, Rietveld M, El Ghalbzouri A, van den Broek PJ, Dijkshoorn L, Nibbering PH. 2012. Three-dimensional human skin equivalent as a tool to study Acinetobacter baumannii colonization. Antimicrob. Agents Chemother. 56:2459-2464.
29. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 48:1-12.
30. Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. 2006. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 129:102-109.
31. Russo TA, Beanan JM, Olson R, MacDonald U, Luke NR, Gill SR, Campagnari AA. 2008. Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology. Infect. Immun. 76: 3577-3586.
32. Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. 2010. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One 5:e10034. doi:10.1371/journal.pone.0010034.
33. Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM, Byun MK. 2012. Clinical outcomes of tigecycline in the treatment of multidrugresistant Acinetobacter baumannii infection. Yonsei Med. J. 53:974-984.
34. Moon SY, Peck KR, Chang HH, Kim SW, Heo ST, Son JS, Ryu SY, Moon C, Jung SI, Shin SY, Lee JA, Joung MK, Chung DR, Kang CI, Song JH. 2012. Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp. Microb. Drug Resist. 18:562-566.
35. Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI, Aydemir S, Bacakoglu F. 2011. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia? J. Chemother. 23: 345-349.
36. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, Nordmann P, Weissenbach J, Raoult D, Claverie JM. 2006. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet. 2:e7. doi:10.1371/journal .pgen.0020007.
37. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. 2004. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48:753-757.
38. Baumann P, Doudoroff M, Stanier RY. 1968. A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). J. Bacteriol. 95:1520-1541.